Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators.
Arnold DL, et al. Among authors: stojanovic m.
Neurology. 2016 Oct 4;87(14):1464-1472. doi: 10.1212/WNL.0000000000003169. Epub 2016 Sep 2.
Neurology. 2016.
PMID: 27590291
Free PMC article.
Clinical Trial.